How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,340 results for

fluoroquinolones

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Out of Asia: the independent rise and global spread of fluoroquinolone-resistant Shigella Full Text available with Trip Pro

Out of Asia: the independent rise and global spread of fluoroquinolone-resistant Shigella Shigella are ranked among the most prevalent aetiologies of diarrhoeal disease worldwide, disproportionately affecting young children in developing countries and high-risk communities in developed settings. Antimicrobial treatment, most commonly with fluoroquinolones, is currently recommended for Shigella infections to alleviate symptoms and control disease transmission. Resistance to fluoroquinolones has (...) emerged in differing Shigella species (S. dysenteriae, flexneri and sonnei) since the turn of the 21st century, originating in endemic areas, and latterly spreading into non-endemic regions. Despite occurring independently, the emergence of fluoroquinolone resistance in these different Shigella species shares striking similarities regarding their epidemiology and resistance mechanisms. Here, we review and discuss the current epidemiology of fluoroquinolone-resistant Shigella species, particularly

2018 Microbial Genomics

102. Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort. Full Text available with Trip Pro

Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort. Fluoroquinolone is a commonly prescribed antimicrobial agent, and up to 20% of its users registers adverse gastroenterological symptoms. We aimed to evaluate the association between use of fluoroquinolone and gastrointestinal tract perforation.We conducted a nested case-control study on a national health insurance claims database between 1998 and 2011. The use (...) of fluoroquinolones was classified into current (< 60 days), past (61-365 days prior to the index date) and any prior year use of fluoroquinolones. We used the conditional logistic regression model to estimate rate ratios (RRs), adjusting or matching by a disease risk score (DRS).We identified a cohort of 17,510 individuals diagnosed with gastrointestinal perforation and matched them to 1,751,000 controls. Current use of fluoroquinolone was associated with the greatest increase in risk of gastrointestinal

2017 PLoS ONE

103. Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? Full Text available with Trip Pro

Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? 29549060 2018 11 05 2018 11 05 1469-0691 24 7 2018 Jul Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases Clin. Microbiol. Infect. Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? 678-679 S1198-743X(18)30208-8 10.1016/j.cmi.2018.02.031 Mikulska M M Division of Infectious Diseases, University of Genoa (DISSAL (...) ) and Ospedale Policlinico San Martino, Genoa, Italy. Electronic address: m.mikulska@unige.it. Cordonnier C C Department of Haematology, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Est-Créteil, Créteil, France. eng Letter 2018 03 13 England Clin Microbiol Infect 9516420 1198-743X 0 Fluoroquinolones IM Antibiotic Prophylaxis Disease Management Drug Resistance, Microbial Fluoroquinolones therapeutic use Hematologic Neoplasms complications therapy Humans Neutropenia

2018 Clinical Microbiology and Infection

104. Delafloxacin: A New Anti-MRSA Fluoroquinolone. (Abstract)

Delafloxacin: A New Anti-MRSA Fluoroquinolone. Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral formulations. It has recently been approved by the Food and Drug Administration for the management of acute bacterial skin and skin structure infections. When compared to combination therapy of vancomycin and aztreonam, delafloxacin was not inferior and had a favorable adverse event profile. Furthermore, its anti-methicillin-resistant Staphylococcus aureus (MRSA (...) ) activity and favorable clinical response in MRSA infections distinguishes it from other fluoroquinolones. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail

2018 Clinical Infectious Diseases

105. Oral Fluoroquinolone Prescribing to Children in the United States From 2006 to 2015. (Abstract)

Oral Fluoroquinolone Prescribing to Children in the United States From 2006 to 2015. Fluoroquinolone (FQ) prescription rates have increased over the last 10 years despite recent warnings of serious adverse effects such as peripheral neuropathy and tendinopathy. Currently, there are no published data on the extent or appropriateness of FQ prescribing in children.Drug prescription data from the PharMetrics Plus health claims database (United States) were analyzed to examine dispensing

2018 Pediatric Infectious Dsease Journal

106. Clinical manifestations, molecular characteristics, antimicrobial susceptibility patterns and contributions of target gene mutation to fluoroquinolone resistance in Elizabethkingia anophelis. Full Text available with Trip Pro

Clinical manifestations, molecular characteristics, antimicrobial susceptibility patterns and contributions of target gene mutation to fluoroquinolone resistance in Elizabethkingia anophelis. Elizabethkingia anophelis has recently emerged as a cause of life-threatening infections in humans. We aimed to investigate the clinical and molecular characteristics of E. anophelis.A clinical microbiology laboratory database was searched to identify patients with Elizabethkingia infections between 2005 (...) -level fluoroquinolone resistance.Minocycline has the potential to be the drug of choice in patients with E. anophelis infections. Additional investigations are needed to determine the optimal antimicrobial agents to treat this life-threatening infection.

2018 Journal of Antimicrobial Chemotherapy

107. Fluoroquinolones in the management of tuberculous meningitis: Systematic review and meta-analysis. (Abstract)

Fluoroquinolones in the management of tuberculous meningitis: Systematic review and meta-analysis. Tuberculous meningitis carries a high rate of mortality and morbidity despite of an adequate treatment. Newer agents are being searched to improve outcome of these patients. Fluoroquinolones might be useful in the management of tuberculous meningitis in view of good cerebrospinal fluid penetration and good in-vitro activity against the mycobacterium. This review summarizes the effects (...) of fluoroquinolone in first line regimens in tuberculous meningitis.A systematic search of literature was performed using PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and LILACS for articles published till march 2017. We also searched meta-register of controlled trials and bibliography of relevant studies. Randomized controlled trials (RCTs) where a fluoroquinolone was administered in addition or substitution of standard antituberculosis drugs formed the basis of selection criteria. Data

2018 Journal of Infection

108. Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. Full Text available with Trip Pro

Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. As information on Ureaplasma spp. and Mycoplasma hominis resistance is currently limited, the aim of this study was to investigate the susceptibility of Ureaplasma spp. and M. hominis to tetracyclines and fluoroquinolones in France.The susceptibility of 1014 clinical isolates obtained in Bordeaux University Hospital (Bordeaux, France) between 2010 and 2015 (...) was evaluated using two commercial kits, S.I.R. Mycoplasma (Bio-Rad) from 1 January 2010 to 5 October 2012 and MYCOFAST RevolutioN kit (ELITech Group) from 6 October 2012 to 31 December 2015. The MICs of isolates designated as resistant were determined using the broth microdilution assay. Additionally, the tet(M) gene and fluoroquinolone resistance-associated mutations were identified.Among 831 Ureaplasma spp. isolates, the tetracycline, levofloxacin and moxifloxacin resistance rates were 7.5%, 1.2% and 0.1

2018 Journal of Antimicrobial Chemotherapy

109. High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals. Full Text available with Trip Pro

High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals. Fluoroquinolone resistance (FQR) in third-generation cephalosporin-resistant Enterobacteriaceae (3GCRE) presents serious limitations to antibiotic therapy. The aim of this study was to investigate whether the FQR proportion among 3GCRE differs between community-acquired (CA) and hospital-acquired (HA) isolates.In a prospective observational study

2018 Journal of Antimicrobial Chemotherapy

110. Overexpression of Stenotrophomonas maltophilia major facilitator superfamily protein MfsA increases resistance to fluoroquinolone antibiotics. Full Text available with Trip Pro

Overexpression of Stenotrophomonas maltophilia major facilitator superfamily protein MfsA increases resistance to fluoroquinolone antibiotics. Stenotrophomonas maltophilia is an opportunistic human pathogen causing nosocomial infections worldwide. S. maltophilia infection is of particular concern due to its inherent resistance to currently used antibiotics. Proton motive force-driven transporters of the major facilitator superfamily frequently contribute to the efflux of substances, including (...) antibiotics, across cell membranes.An mfsA expression plasmid (pMfsA) was constructed and transferred into bacterial strains by electroporation. The antibiotic susceptibility levels of S. maltophilia strains were determined using standard methods.S. maltophilia MfsA is an efflux pump associated with paraquat resistance. We show here that plasmid-mediated overexpression of mfsA in WT S. maltophilia K279a increased resistance not only to paraquat but also to second-generation fluoroquinolone antibiotics

2018 Journal of Antimicrobial Chemotherapy

111. High prevalence of fluoroquinolone resistance amongst commensal flora of antibiotic naïve neonates: a study from India. Full Text available with Trip Pro

High prevalence of fluoroquinolone resistance amongst commensal flora of antibiotic naïve neonates: a study from India. The emergence of resistance amongst commensal flora is a serious threat to the community. However, there is paucity of data regarding antibiotic resistance in commensals in the absence of antibiotic pressure.Altogether, 100 vaginally delivered antibiotic naïve exclusively breastfed neonates were selected. Stool samples collected on day (D)1, D21 and D60 of birth were cultured (...) were isolated from 100 neonates. On D1, 58 % of neonates were colonized with at least one Enterobacteriaceae predominantly E. coli. Overall resistance to NA was 60 % but ciprofloxacin resistance increased significantly from 15 % (14/96) on D1 to 38 % (50/132) on D60 (P-value <0.001). The predominant mechanism of fluoroquinolone resistance was mutation in gyrA (n=49) with or without PMQR. PMQR carrying isolates increased more than fivefold from D1 to D60.A high level of fluoroquinolone resistance

2018 Journal of Medical Microbiology

112. Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study. Full Text available with Trip Pro

Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study. Fluoroquinolones (FQ) are increasingly prescribed for children, despite being labeled for only a limited number of labeled pediatric indications. In this multicenter retrospective drug utilization study, we analyzed indications for systemic FQ prescriptions in hospitalized children and the appropriateness of the prescribed dose.Using data obtained from

2018 BMC Infectious Diseases

113. In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains. Full Text available with Trip Pro

In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains. Mycoplasma genitalium is estimated to be the second most common cause of bacterial sexually transmitted infection in Europe. It is of increasing public health concern due to the rapid development of resistance to different antimicrobial classes, including the preferred first- and second-line treatments azithromycin and moxifloxacin. Thus

2018 Journal of Antimicrobial Chemotherapy

114. Clinical review of delafloxacin: a novel anionic fluoroquinolone. Full Text available with Trip Pro

Clinical review of delafloxacin: a novel anionic fluoroquinolone. Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive and Gram-negative organisms including MRSA and Pseudomonas aeruginosa. The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in acidic environments. In Phase III studies, delafloxacin had similar outcomes

2018 Journal of Antimicrobial Chemotherapy

115. Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. Full Text available with Trip Pro

Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolones are not recommended first-line therapy. Unnecessary fluoroquinolone use should be reduced.

2018 Clinical Infectious Diseases

116. Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients

Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients (PERFECT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

117. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: A systematic review and meta-analysis. (Abstract)

Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: A systematic review and meta-analysis. Fluoroquinolones are a popular alternative to trimethoprim-sulfamethoxazole for Stenotrophomonas maltophilia infections.To compare the effects of fluoroquinolones and trimethoprim-sulfamethoxazole on mortality of S. maltophilia infections.PubMed and EMBASE.Clinical studies reporting mortality outcomes of S. maltophilia infections.Patients (...) with clinical infections caused by S. maltophilia.Fluoroquinolone monotherapy in comparison with trimethoprim-sulfamethoxazole monotherapy.Systematic review with meta-analysis technique.Seven retrospective cohort and seven case-control studies were included. Three cohort studies were designed to compare the two drugs, whereas others had other purposes. A total of 663 patients were identified, 332 of which were treated with trimethoprim-sulfamethoxazole (50.1%) and 331 with fluoroquinolones (49.9%). Three

2018 Clinical Microbiology and Infection

118. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. (Abstract)

Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. The goal of this study was to investigate whether ceftriaxone combination therapy is associated with better clinical outcomes than respiratory fluoroquinolone monotherapy for adults with community-acquired pneumonia (CAP). We conducted a meta-analysis of published studies.Using the PubMed, EMBASE, and Cochrane Library databases, we performed a literature search (...) of available randomized controlled trials (RCTs) published as original articles before September 2017.Nine RCTs, involving 1520 patients, were included in the meta-analysis. The pooled relative risks (RRs) for the efficacy of ceftriaxone combination therapy versus respiratory fluoroquinolones monotherapy were 0.96 (95% CI: 0.92-1.01), based on clinically evaluable populations, and 0.93 (95% CI: 0.88-0.99) based on intention-to-treat (ITT) populations. No statistically significant differences were observed

2018 American Journal of Emergency Medicine

119. Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin/Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing. (Abstract)

Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin/Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing. To compare 3 prophylactic regimens to assess their impact on postbiopsy sepsis incidence.Data were reviewed for 829 consecutive patients who underwent prostate biopsy in a community practice setting between January 2013 and October 2017. Group 1 patients received ciprofloxacin 500 mg two times a day orally for 4 days starting the day prior to biopsy

2018 Urology

120. BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections Full Text available with Trip Pro

BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections Baxdela (delafloxacin) for treatment of acute bacterial skin and skin structure infections.

2018 Pharmacy and Therapeutics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>